Insight

Armando Orlandi: Our new study on HER2-low luminal BC is Riding Breast Cancer’s Biggest Data’s Wave

Armando Orlandi/photos.asco.org

Mar 28, 2025, 16:06

Armando Orlandi: Our new study on HER2-low luminal BC is Riding Breast Cancer’s Biggest Data’s Wave

Armando Orlandi, Medical Director at the Agostino Gemelli University Hospital Foundation IRCCS, shared a post on

“Cowabunga! Riding Breast Cancer’s Biggest Data’s Wave from Literature

Our new study on HER2-low luminal BC is making waves!

566 patients showed tricky patterns: lower pCR rates (13.2% vs 17.7%) but trending toward better survival for HER2-low.”

Activity and Efficacy of Neoadjuvant Chemotherapy in Luminal-HER2 Negative Early Breast Cancer According to HER2 Score (Low vs. Score 0): A Retrospective Study

Authors: Giovanna Garufi, Armando Orlandi et al

Armando Orlandi

Alessandra Fabi Angelachiara Rotondi Antonella Palazzo Antonio Franco Armando Orlandi cancer Carbognin Luisa Elena Di Monte Emilio Bria Fabio Marazzi Giampaolo Tortora Gianluca Franceschini Giorgia Arcuri Giovanna Garufi Giovanni Scambia Ida Paris Luca Mastrantoni Noemi Maliziola OncoDaily Oncology Valentina Frescura

Meet the New AACR Board of Directores for 2025-2028 Term

Do Artificial Sweeteners Cause Cancer? Myths and Facts

King Charles III Hospitalized Following Side Effects from Cancer Treatment

Keith T. Flaherty has been elected as the AACR President-Elect for 2025-2026

MARIPOSA trial results presented at ELCC25 - BREAKING from Paris